SurModics Corporate History
The company was formed in 1979 by three scientists to develop and commercialize diagnostic and medical/pharmaceutical products from their organic, photochemical, and immunodiagnostic expertise.
In 1987, the company shifted its strategic objective from contract research to the commercialization of its unique PhotoLink surface modification and immobilization technologies, and in 1990, added the marketing of biomolecule stabilization products.
In July 1997, BSI Corporation changed its name to SurModics, Inc. to more accurately reflect the company's current and future business focus in the field of surface modification. SurModics became a public company (Nasdaq National Market: SRDX) on March 4, 1998.
SurModics is now a leading provider of drug delivery and surface modification technologies in the areas of: site-specific and systemic drug delivery, advanced hydrophilic coatings, biocompatible and prohealing coatings, ophthalmology, tissue engineering, in vitro technologies, and cell culture surfaces.
In July 2007, SurModics acquired Brookwood Pharmaceuticals, Inc., a leading provider of drug delivery technology primarily to the pharmaceutical industry, from Southern Research Institute. The addition of Brookwood’s core capabilities, injectable microparticles and implant technology, further strengthen SurModics' position as a leading company in polymer based drug delivery. Our collective technology enables us to offer both site specific and systemic drug release capabilities to a broad range of customers in several large markets.
SurModics further broadened its product portfolio within the in vitro diagnostics market through the acquisition of BioFX, a developer, manufacturer and marketer of colorimetric and chemiluminescent substrates, in August 2007.
Our technology portfolio enables us to serve numerous clinical areas and markets, including diabetes, oncology, ophthalmology, cardiovascular, orthopedics, and central nervous system (CNS) and other fields.
Representative examples of our efforts include:
- Implementation of our Bravo™ Drug Delivery Polymer Matrix as a key component of the Cypher® Sirolimus-eluting Coronary Stent from Cordis Corporation, a Johnson & Johnson company
- Development of the I-vation™ Sustained Drug Delivery System that is currently in human trials for treatment of retinal disease
- Implementation of our hydrophilic coatings on various drug-eluting stent delivery systems, atherectomy systems, catheters, and guidewires
- Joint development of Ultra-Web™ Synthetic ECM (extracellular matrix) surfaces for cell culture with Donaldson Company
SurModics partners with the world's foremost medical device, pharmaceutical, and life science companies, and is bringing innovation together to enhance the well-being of patients.